Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sohm Inc (OP:SHMN)

0.0013 +0.0001 (+8.33%)
Streaming Delayed Price Updated: 10:53 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sohm Inc

< Previous 1 2 3 Next >
SOHM, Inc. Announces Allowance of Another Divisional Patent in the Republic of South Korea
Via ACCESS Newswire
SOHM, Inc., Moving and Expanding Commercialization Capabilities with its New Vista, CA Facility
Via ACCESS Newswire
SOHM Achieves Breakthrough with ABBIE Gene Editing Platform, Advancing Strategic Partnership and Licensing Opportunities
Via ACCESS Newswire
SOHM, Inc. Launches New User-Friendly Website to Enhance Customer, Investor Experience and Engagement
Via ACCESS Newswire
SOHM, Inc. Appoints Ravi Kapoor as an Independent Director
Via ACCESS Newswire
SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders
Via ACCESSWIRE
Rheumatoid Arthritis Patients Face Heightened Risk of Depression, Study Finds
Via Investor Brand Network
SOHM, Inc. Sets Strategic Goals to Enter Biotechnology-Driven Cosmeceuticals Market
Via ACCESS Newswire
SOHM Inc. Welcomes Dr. Larissa Karnaoukhova as New Vice President of Operations
Via ACCESS Newswire
SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development
Via ACCESS Newswire
SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery
Via ACCESS Newswire
Why Prescription Drugs Can Be Costly
Via Investor Brand Network
Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization
Via ACCESS Newswire
SOHM Inc. Awarded European Patent for Innovative ABBIE Genome Editing Technology
Via ACCESS Newswire
SOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies
Via ACCESS Newswire
SOHM, Inc. Announces Patent Allowance/Approval in South Korea
Via ACCESS Newswire
SOHM, Inc. Shares an Exciting Expansion and Upcoming Presentation on ABBIE
Via ACCESS Newswire
SOHM, Inc. Launches New AI Team to Advance ABBIE System and Genome Editing Innovations
Via ACCESS Newswire
SOHM, Inc. Shares Groundbreaking Findings in ABBIE Technology
Via ACCESS Newswire
SOHM, Inc. Announce Dr. Wei Zhu Onboard as Senior Marketing and Sales Consultant
Via ACCESSWIRE
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (特許庁, Tokkyochō, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes
Via ACCESSWIRE
SOHM, Inc. Announce Dr. David Zarling Onboard as Senior Product Development Advisor
Via ACCESSWIRE
SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
Via ACCESSWIRE
SOHM, Inc., Announce Dr. Tetsuya Kawamura Ph. D. Joined as a Cell Engineer and Biochemist
Via ACCESSWIRE
SOHM, Inc. has signed the Manufacturing and Supply of Skincare Topical Products with New Export Customers
Via ACCESSWIRE
SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University
Via ACCESSWIRE
SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell immunotherapy from a Healthy Human Donor
Via ACCESSWIRE
BioMedNewsBreaks — SOHM, Inc. (SHMN) Continues to Advance Groundbreaking Technology
Via Investor Brand Network
InvestorNewsBreaks – SOHM, Inc. (SHMN), Coastar Therapeutics Collaborate to Advance Field of Genome Editing
Via Investor Brand Network
FDA Grants Florida Permission to Import More Affordable Medicines from Canada
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.